Osmotica Pharmaceuticals plc announced that Brian Markison, Chief Executive Officer, James “JD” Schaub, Chief Operating Officer, and other key speakers, will host a call to discuss recent UPNEEQ® trends, pending expansion into the medical Aesthetics market and other general business updates as follows.
BRIDGEWATER, N.J., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a specialty pharmaceutical company, announced today that Brian Markison, Chief Executive Officer, James “JD” Schaub, Chief Operating Officer, and other key speakers, will host a call to discuss recent UPNEEQ® trends, pending expansion into the medical Aesthetics market and other general business updates as follows:
| Date: | Wednesday, January 19, 2022 |
| Time: | 8:30 a.m. ET |
| Webcast: | https://experience.v-unite.com/#/aestheticrecorddemo/rvlinvestorday/room/welcome |
The webcast will be available thereafter via the Company’s website at www.rvlpharma.com under the “Investor & News” section.
About Osmotica Pharmaceuticals plc
Osmotica Pharmaceuticals plc (Nasdaq: OSMT) is a specialty pharmaceutical company focused on the development and commercialization of products that target markets with underserved patient populations. RVL Pharmaceuticals, Inc., is the Company’s ophthalmic and medical aesthetics subsidiary supporting UPNEEQ®.
Investor and Media Relations for Osmotica Pharmaceuticals plc
Lisa M. Wilson
In-Site Communications, Inc.
T: 212-452-2793
E: lwilson@insitecony.com
